reference/36381954

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/36381954

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, Non-U.S. Gov't
issn	2001-3078
issueIdentifier	11
pageRange	e12379-
publicationName	Journal of Extracellular Vesicles
startingPage	e12379
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c58b8f098bb80fdeab2f5465eb269619 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_eb074666a91166065aacae403afee8d9 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_1e75a8d80bde809a0192174998e32895 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_487baf6554eb36bb22c6138d90a7c50f http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_7ae88100ecf50b03d1a9926d6373cde2 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_1c0aa062611518a12552a116a65f748d http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_e80efd80dadfbd83d5e9ba7055a93d17 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_dbae2a3af0b52022c87ff6fdcc279147
bibliographicCitation	Zhang L, Zhao X, Niu Y, Ma X, Yuan W, Ma J. Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy. J Extracell Vesicles. 2023 Nov;12(11):e12379. PMID: 37974395; PMCID: PMC10654473.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-9642-4606 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8dd3822d33760def7aeb65d681e19aca http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-5840-4863 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a3543ef20ab87249bcb63905231b4e4b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_700ea5187e6c33fa6237ba895ba93ede http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-2938-818X
date	202311
identifier	https://doi.org/10.1002/jev2.12379 https://pubmed.ncbi.nlm.nih.gov/PMC10654473 https://pubmed.ncbi.nlm.nih.gov/37974395
isPartOf	https://portal.issn.org/resource/ISSN/2001-3078 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/41559
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Engineering high‐affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy
discusses	http://id.nlm.nih.gov/mesh/M0555734 http://id.nlm.nih.gov/mesh/M0221607 http://id.nlm.nih.gov/mesh/M0001357 http://id.nlm.nih.gov/mesh/M0556121
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D009369Q000473 http://id.nlm.nih.gov/mesh/D000067128Q000378
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D007167 http://id.nlm.nih.gov/mesh/D061026Q000627 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D051928Q000378 http://id.nlm.nih.gov/mesh/D000911 http://id.nlm.nih.gov/mesh/D060890

Showing number of triples: 1 to 43 of 43.